Cognition Therapeutics (CGTX) Competitors $0.44 0.00 (-0.82%) Closing price 04/25/2025 04:00 PM EasternExtended Trading$0.44 +0.00 (+0.96%) As of 04/25/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CGTX vs. ALEC, BHST, KYTX, EXOZ, XBIT, TLSA, ORMP, OPTN, COYA, and CLYMShould you be buying Cognition Therapeutics stock or one of its competitors? The main competitors of Cognition Therapeutics include Alector (ALEC), BioHarvest Sciences (BHST), Kyverna Therapeutics (KYTX), Exozymes (EXOZ), XBiotech (XBIT), Tiziana Life Sciences (TLSA), Oramed Pharmaceuticals (ORMP), OptiNose (OPTN), Coya Therapeutics (COYA), and Climb Bio (CLYM). These companies are all part of the "pharmaceutical products" industry. Cognition Therapeutics vs. Alector BioHarvest Sciences Kyverna Therapeutics Exozymes XBiotech Tiziana Life Sciences Oramed Pharmaceuticals OptiNose Coya Therapeutics Climb Bio Cognition Therapeutics (NASDAQ:CGTX) and Alector (NASDAQ:ALEC) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their community ranking, earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk. Which has better earnings and valuation, CGTX or ALEC? Cognition Therapeutics has higher earnings, but lower revenue than Alector. Alector is trading at a lower price-to-earnings ratio than Cognition Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCognition TherapeuticsN/AN/A-$25.79M-$0.87-0.50Alector$100.56M1.12-$130.39M-$1.23-0.93 Is CGTX or ALEC more profitable? Cognition Therapeutics has a net margin of 0.00% compared to Alector's net margin of -257.54%. Alector's return on equity of -108.77% beat Cognition Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Cognition TherapeuticsN/A -150.93% -100.82% Alector -257.54%-108.77%-27.03% Do analysts recommend CGTX or ALEC? Cognition Therapeutics currently has a consensus target price of $7.13, suggesting a potential upside of 1,527.46%. Alector has a consensus target price of $3.50, suggesting a potential upside of 207.02%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Alector.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cognition Therapeutics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Alector 2 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.14 Do institutionals & insiders hold more shares of CGTX or ALEC? 43.3% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 85.8% of Alector shares are held by institutional investors. 20.8% of Cognition Therapeutics shares are held by company insiders. Comparatively, 9.1% of Alector shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has more volatility and risk, CGTX or ALEC? Cognition Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Alector has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500. Does the media refer more to CGTX or ALEC? In the previous week, Alector had 2 more articles in the media than Cognition Therapeutics. MarketBeat recorded 3 mentions for Alector and 1 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 1.87 beat Alector's score of 1.61 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Cognition Therapeutics Very Positive Alector Very Positive Does the MarketBeat Community believe in CGTX or ALEC? Alector received 132 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. However, 72.73% of users gave Cognition Therapeutics an outperform vote while only 60.94% of users gave Alector an outperform vote. CompanyUnderperformOutperformCognition TherapeuticsOutperform Votes2472.73% Underperform Votes927.27% AlectorOutperform Votes15660.94% Underperform Votes10039.06% SummaryCognition Therapeutics beats Alector on 12 of the 18 factors compared between the two stocks. Get Cognition Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CGTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CGTX vs. The Competition Export to ExcelMetricCognition TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$27.13M$2.92B$5.44B$7.80BDividend YieldN/A1.91%5.43%4.30%P/E Ratio-0.4529.2222.1418.40Price / SalesN/A481.28389.70101.29Price / CashN/A168.6838.2034.62Price / Book0.583.036.664.18Net Income-$25.79M-$72.17M$3.21B$247.71M7 Day Performance17.56%8.86%6.16%6.56%1 Month Performance-0.86%-3.99%-2.86%-2.25%1 Year Performance-77.55%-21.17%16.43%4.67% Cognition Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CGTXCognition Therapeutics3.1221 of 5 stars$0.44-0.8%$7.13+1,527.5%-77.3%$27.13MN/A-0.4520Positive NewsGap DownALECAlector3.5627 of 5 stars$0.98+3.2%$3.50+256.9%-76.3%$97.18M$100.56M-0.58270News CoveragePositive NewsBHSTBioHarvest SciencesN/A$5.90+5.2%$13.00+120.3%N/A$96.91M$25.19M-4.72N/AUpcoming EarningsNews CoverageHigh Trading VolumeKYTXKyverna Therapeutics1.4663 of 5 stars$2.23+8.3%$18.33+722.1%-86.8%$96.37M$7.03M-0.6496Gap DownEXOZExozymesN/A$11.39+4.5%N/AN/A$95.31MN/A0.0029Gap UpXBITXBiotech0.9379 of 5 stars$3.12-4.9%N/A-64.6%$95.12M$4.01M-2.89100News CoveragePositive NewsTLSATiziana Life Sciences1.0185 of 5 stars$0.80+1.3%N/A+60.0%$93.49MN/A0.008Positive NewsORMPOramed Pharmaceuticals1.5031 of 5 stars$2.27+7.6%N/A+1.3%$92.73M$1.34M20.6410News CoveragePositive NewsGap UpOPTNOptiNose3.2693 of 5 stars$9.10+0.3%$9.00-1.1%-31.6%$91.66M$78.23M-2.17190Positive NewsCOYACoya Therapeutics2.4945 of 5 stars$5.45+5.4%$17.00+211.9%-26.7%$91.15M$3.55M-8.386Analyst ForecastNews CoveragePositive NewsCLYMClimb Bio2.4741 of 5 stars$1.31+2.3%$10.00+663.4%N/A$88.39MN/A-0.629 Related Companies and Tools Related Companies Alector Competitors BioHarvest Sciences Competitors Kyverna Therapeutics Competitors Exozymes Competitors XBiotech Competitors Tiziana Life Sciences Competitors Oramed Pharmaceuticals Competitors OptiNose Competitors Coya Therapeutics Competitors Climb Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CGTX) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cognition Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
